ArticleNPJ precision oncology2026
Concordance analysis of non-invasive techniques for PIK3CA and ESR1 mutations in advanced HR+/HER2- breast cancer: the CANIPE study.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer represents ~70% of breast tumors. Accurate detection of PIK3CA and ESR1 mutations is crucial for guiding targeted therapies, particularly in advanced disease. Liquid biopsy testing is increasingly recommended, especially for ESR1 mutation, but standardized genotyping methods remain limited. The CANIPE study, a prospective, multicenter Spanish trial, evaluated mutation prevalence in 106 baseline blood samples. PIK3CA mutations were identified in 41.9% by ddPCR droplet digital PCR (ddPCR) and 42.8% by targeted next-generation sequencing (NGS), while ESR1 mutations were detected in 7.8 and 9.5%, respectively. A concordance analysis between ddPCR and NGS was performed in 62 paired samples, demonstrating excellent agreement (Kappa >0.85) and strong correlation in variant allele frequency for PIK3CA, confirming the reliability of the methods. Baseline circulating free DNA levels were prognostic for survival. These results, derived from real-world patient samples, support ddPCR and NGS as robust, complementary tools for mutation detection and therapeutic decision-making.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.